Leading ECG analysis platform speeds time to diagnosis and creates greater clinical efficiencies

BELLEVUE, Washington (June 21, 2021) — Cardiac Insight, Inc.(“Cardiac Insight” or the “Company”) is a US-based healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and diagnosis of cardiac arrhythmias, such as atrial fibrillation (AFib). The Company is launching its Cardea SOLO™ ECG System (“Cardea SOLO”) at Arab Health 2021, the largest healthcare exhibition in the Middle East.

Cardea SOLO™ combines a single-use patient-friendly wearable ECG sensor with 100% in-clinic automated software managed by clinicians – the only solution of its kind. The Cardea SOLO, with its proven arrhythmia analysis technology, includes comprehensive report generation and clinical editing tools for the full disclosure data, creating efficiencies and reduced processing time for clinicians.

The platform facilitates improved patient care and better patient compliance while keeping patient data securely in-house and enhancing overall cybersecurity for hospitals and clinicians, including cardiologists and electrophysiologists.

“Cardiac Insight continues to expand globally. We are pleased to participate in Arab Health 2021. Our goal is to increase awareness about our innovative FDA-cleared Cardea SOLO wearable ECG system and promote new clinical and business development partnerships in the Middle East to reach more patients,” said Brad Harlow, Cardiac Insight’s CEO. “The Cardea SOLO revolutionizes the cardiac arrhythmia diagnostic process by replacing bulky, wired Holter ECG monitors with patient-friendly ECG wearables that improve diagnostic yield, speed the time to diagnosis, streamline workflows, and ultimately elevate the standard of care.”

The Cardea SOLO wearable single-use ECG sensor is typically applied to the patient in a hospital, clinic or physician’s office and can be made available for telehealth options. After an optimal seven-day wear period, the patient removes and returns their sensor to their physician’s office by mail or in person. Cardea SOLO’s robust, algorithm-based ECG software produces a comprehensive draft report which facilitates prompt clinical review and decision-making, reducing the overall time to diagnosis and treatment.

Follow Cardiac Insight on LinkedIn, Twitter and Facebook for the latest information.
Media Contact: Carla Pagotto ([email protected])

ABOUT CARDIAC INSIGHT, INC: Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn wearable ECG sensor technology and automated cardiac analysis solutions through its advanced proprietary algorithms and software platforms. The company’s point of care products include the Cardea SOLO™ wearable ECG Sensor and Software Analysis System, and the Cardea 20/20 ECG™ – the only resting ECG System designed for cardiac risk screening in young athletes at all levels of play. Cardiac Insight sells direct and through its authorized representatives to healthcare systems and diverse physicians, including cardiologists, and electrophysiologists. The Company also supports academic cardiac research working with leading centers worldwide as well as pharmaceutical and OTC digital health companies.